Views & Analysis Budget impact and cost effectiveness: alternatives to NICE a... A new way to capture when drugs are ‘cost effective’ but not ‘affordable’ looks set to be introduced in England.
Views & Analysis The budget impact of new medicines What could be the impact of proposed new ‘budget impact threshold’ for drugs?
Views & Analysis Fast-track appraisals and Managed Access Agreements Experts discuss England’s proposed ‘fast-track’ appraisals for new treatments, plus MAAs.
Views & Analysis High-value, high-cost drugs: how to pay for them Experts call for urgent development of new drug funding mechanisms.
Views & Analysis Getting it right: the UK’s pathway for 2017 The implications for global pharma HQs and what the UK needs to do.
Views & Analysis Who needs (early) advice? You do! The prospects for HTA Early Scientific Advice programmes.
Digital The TechBio way: Brendan Frey talks genomics, AI, and RNA pharmaphorum speaks with Brendan Frey, founder and chief innovation officer of Deep Genomics, an AI-first TechBio organisation.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face
